Madrid, 29th June 2021 – The Spanish biotech company Tetraneuron, specialised in the research and development of a gene therapy for Alzheimer’s disease (AD), has closed a new financing round of more than €2.5 million. This additional capital will allow for the consolidation of the company as well as the acceleration of its roadmap; validated by the main regulatory agencies, which aims to start a clinical trial for its therapy against AD.
As the first Spanish biotech resident at Johnson & Johnson Innovation, JLABS, Tetraneuron is developing an advanced therapy for Alzheimer’s disease through a therapeutic approach based on E2F4, a protein involved in the origin of the pathogenesis of this complicated disease. With encouraging preclinical results in AD mice model with an aggravated disease phenotype, the company is pursuing a multifactorial approach to Alzheimer’s through gene therapy that is expected to slow the progression of a disease that currently affects more than 50 million people in the world. Unlike other strategies, since its foundation, Tetraneuron has provided a totally disruptive vision by tackling the global causes of the disease.
Led by Dr. José María Frade, researcher at the Cajal Institute and a global reference in the field of neuronal cell cycle reactivation, Tetraneuron was born as a spin-off of the Cajal Institute, part of the Spanish National Research Council (CSIC), and has been funded by private investors from the outset. In this new round, investors specialised in the biopharmaceutical sector and advanced therapies have joined the company. The company, has been advised by Borealis Corporate Finance in the investment process, and will begin a new international financing round during the first quarter of 2022.
The progress of gene therapy, currently under development, is evident in some recent success stories and opens up a new horizon for the possibility of curing diseases without a current effective treatment. The good results obtained in areas such as Ophthalmology or Oncology endorse the promising transcendence of these therapies in the future for other pathologies.
In line with this, Tetraneuron is expanding its portfolio of innovative products by developing a biomarker for the early diagnosis of AD, as well as in the search for new therapeutic indications for its gene therapy.
For further information,
Mari Carmen Álvarez (email@example.com)
David Mor (firstname.lastname@example.org)